Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease

Figures & data

Table 1 Baseline characteristics of CKD patients

Variables	Paroxetine	Agomelatine	p-value
n	49	50	–
Age (years)	51.43 (9.38)	52.60 (9.55)	0.54
Education (years)	8.31 (3.08)	8.22 (2.89)	0.87
Duration of CKD (years)	2.79 (0.85)	2.75 (0.81)	0.81
BMI (kg/m^2)	22.98 (3.21)	22.61 (3.53)	0.58
Female/male	20/29	18/32	0.62
Single household (Y/N)	12/37	14/36	0.69
Smoking (Y/N)	15/34	21/29	0.24
Alcohol abuse (Y/N)	5/44	9/41	0.27
Diabetes mellitus (Y/N)	30/19	28/22	0.60
CKD by stage (2/3/4)	12/27/10	10/29/11	0.86
HDRS scores	23.61 (2.86)	23.62 (2.95)	0.98
HARS scores	18.73 (3.06)	18.46 (3.54)	0.68
ADL scores	28.20 (5.40)	28.06 (6.84)	0.91

Note: Data shown as mean (standard deviation) unless indicated otherwise.

Abbreviations: CKD, chronic kidney disease; BMI, body mass index; HDRS, Hamilton Depression Rating Scale; HARS, Hamilton Anxiety Rating Scale; ADL, Activities of Daily Living.

Figure 1 HDRS scores in the two groups at baseline, week 4, week 8, and week 12.

Abbreviation: HDRS, Hamilton Depression Rating Scale.

Figure 2 HARS scores in the two groups at baseline, week 4, week 8, and week 12.

Abbreviation: HARS, Hamilton Anxiety Rating Scale.

Figure 3 ADL scores in the two groups at baseline and week 12.

Abbreviation: ADL, Activities of Daily Living.